Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway
Li J, Sha X, LoRusso P. Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway. Journal Of Clinical Oncology 2009, 27: e14556-e14556. DOI: 10.1200/jco.2009.27.15_suppl.e14556.Peer-Reviewed Original ResearchGenetic variantsMetabolic pathwaysDNA break repairABT-888Significant genetic variantsTherapeutic outcomesBreak repairCytochrome P450Ongoing phase I trialMolecular basisWild-type CYP2D6Advanced solid tumorsPhase I trialRecombinant human cytochrome P450DNA damageHuman liver microsomesMetabolite formationVariant enzymeMultiple cytotoxic agentsTumor drug concentrationsPARP activityFunctional significanceMajor enzymePredominant enzymeHuman cytochrome P450
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply